These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25694462)

  • 1. Should patients on vitamin K antagonists be treated differently?
    Pokorney SD; Granger CB
    Eur Heart J; 2015 Jun; 36(23):1431-3. PubMed ID: 25694462
    [No Abstract]   [Full Text] [Related]  

  • 2. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
    Plitt A; Giugliano RP
    Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
    [No Abstract]   [Full Text] [Related]  

  • 3. Edoxaban (Lixiana°).
    Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
    Plitt A; Ezekowitz MD; De Caterina R; Nordio F; Peterson N; Giugliano RP;
    Clin Cardiol; 2016 Jun; 39(6):345-6. PubMed ID: 27028520
    [No Abstract]   [Full Text] [Related]  

  • 5. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
    O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
    Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin pharmacogenetics in the era of new oral anticoagulants.
    Wright GE
    Clin Genet; 2015 Aug; 88(2):135-6. PubMed ID: 25970639
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenomic testing and response to warfarin.
    Wu AH
    Lancet; 2015 Jun; 385(9984):2231-2. PubMed ID: 25769360
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anticoagulation for patients with non-valvular atrial fibrillation].
    Mizoguchi T; Yasaka M
    Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
    Huynh K
    Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
    [No Abstract]   [Full Text] [Related]  

  • 11. [Large studies of NOAC shows good and safe stroke protection].
    Hijazi Z; Oldgren J
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
    [No Abstract]   [Full Text] [Related]  

  • 12. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Holden A; Azimi N; Forest CP
    JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
    Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The ENGAGE AF-TIMI 48 study].
    Rubboli A; Colonna P
    G Ital Cardiol (Rome); 2015 Sep; 16(9):457-61. PubMed ID: 26418383
    [No Abstract]   [Full Text] [Related]  

  • 18. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
    Rasmussen KL; Hampton MD
    JBI Database System Rev Implement Rep; 2016 Jun; 14(6):69-77. PubMed ID: 27532651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.